Our end-of-year Exploration goes super-sized as we match up 16 of the most exciting opportunities in our universe of stocks, in search of one winner to kick off 2017.
The Soros Fund showed a healthy appetite for biotech stocks in Q3 -- ignoring the political risk.
The Fidelity Select Health Care Fund is a top healthcare fund thanks to bold bets on its favorite stock picks.
Here's why Amgen, Gilead Sciences, and Lilly just might have paid a lower effective tax rate than you did in 2015.
Poor Q3 results combined with allegations of submitting claims for deceased patients equals a bad day.
Here's what you need to know about what Amgen's management said in the biotech's Q3 earnings call.
Market potential for Nuplazid and a lower market cap could make ACADIA a prime acquisition target.
Here's why AMN Healthcare Services, Air Methods, and AmerisourceBergen look like healthcare bargains.
Our healthcare contributors think these pharma companies deserve a closer look from investors.
This $4.3 billion acquisition is expected to be modestly accretive to Johnson & Johnson's bottom line.